Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tafenoquine vs Primaquine for Radical Cure of P. Vivax Malaria in India
NCT06666491Phase 3Recruiting
- Sponsor
- GSK
- Start
- Nov 2024
- Primary completion
- May 2027
- Modality
- Classical Binding Small Molecules, Nucleic Acid-Directed Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of tafenoquine in vivax malaria, sponsored by GSK. Started Nov 2024; status: recruiting.
02
Drugs
tafenoquine
03
Conditions
vivax malaria
Beyond the preview
Go deeper on NCT06666491.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06666491.